Author: Tessera Therapeutics

Posted Date:

May 14, 2026

Tessera Therapeutics Showcases New Preclinical Data Advancing In Vivo Program in Sickle Cell Disease and CAR-T Applications at the American Society of Gene and Cell Therapy 29th Annual Meeting

Tessera Therapeutics

May 14, 2026
Tessera Therapeutics to Present New Preclinical Data Supporting In Vivo Program in Sickle Cell Disease and Advancements in In Vivo CAR-T Applications at the American Society of Gene and Cell Therapy 29th Annual Meeting

Tessera Therapeutics

May 7, 2026
Tessera Therapeutics Receives Grant to Advance In Vivo Gene Writing Approaches Towards a Potential Human Immunodeficiency Virus (HIV) Cure

Tessera Therapeutics

May 4, 2026
Tessera Therapeutics Receives U.S. FDA Fast Track and Orphan Drug Designations for its Lead In Vivo Gene Editing Program TSRA-196 for the Treatment of Adults with AATD

Tessera Therapeutics

February 23, 2026